Tirzepatide 30mg
Dual receptor agonist. Clinically studied, research-grade supply.
Tirzepatide is a dual receptor agonist, engaging both GLP-1 and GIP receptors. It is the compound behind two FDA-approved pharmaceutical products (used under different branding and indications), and continues to be studied in ongoing clinical research into metabolic and appetite-regulation pathways. Supplied for laboratory research purposes only.
£74.99
9 in stock · BAC Water included free
COA available on request · Same-day dispatch before 2pm
Tirzepatide has been investigated in Phase 3 clinical trials (the SURMOUNT programme) studying combined GLP-1/GIP receptor agonism. Trial data is publicly available in peer-reviewed literature (e.g. NEJM) for independent review.
Tirzepatide activates both GLP-1 and GIP receptors. GLP-1 agonism reduces appetite and slows gastric emptying; GIP agonism amplifies insulin secretion and acts on adipose tissue directly. The combination produces a distinct receptor engagement profile compared to single-agonist compounds.
Supplied as lyophilised powder. Reconstitute with bacteriostatic water before use. Requires refrigeration after reconstitution. For research purposes only.
For laboratory research use only. Not for human consumption. Not intended to diagnose, treat, cure, or prevent any disease. No claims are made regarding safety or efficacy in humans.